ArticlesAtenolol in hypertension: is it a wise choice?
Introduction
β blockers have long been considered to be well documented first-line drugs in the treatment of hypertension.1 Moreover, atenolol is one of the most widely used β blockers clinically, and it has often been used as a reference drug in randomised controlled trials of hypertension.2, 3, 4, 5 Questions have been raised about β blockers as first-line treatment options in hypertension.6 In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial, losartan was shown to be more effective than atenolol in hypertensive patients with left ventricular hypertrophy.4 Whether the result of the LIFE study was caused by a beneficial effect of losartan or a weak effect of atenolol on cardiovascular disease, or both, has been debated.7 The effect of atenolol after myocardial infarction has also been questioned.8 Hence, the aim of our investigation was to systematically review the effect of atenolol on cardiovascular morbidity and mortality in hypertensive individuals.
Section snippets
Methods
We reviewed randomised controlled trials that assessed the effect of atenolol on cardiovascular morbidity or mortality in patients with primary hypertension. Studies were identified though searching of The Cochrane Library, MEDLINE, textbooks, and by personal communication with established researchers in hypertension. The following keywords were used in the database search: atenolol (MESH) OR atenolol “text” AND cerebrovascular disorders (MESH) OR myocardial infarction (MESH); atenolol AND
Results
17 randomised controlled trials were identified in which atenolol was used in one of the treatment arms of hypertension (panel). Five studies were excluded since atenolol was one of two or more drug alternatives in the same treatment arm.9, 10, 11, 12, 13 One was excluded since it compared multidrug strategies rather than individual agents.14 Three studies were excluded since atenolol was an add-on drug.15, 16, 17
In two studies that were included,18, 19 the population of interest was patients
Discussion
The present analysis casts doubts on atenolol as a suitable first-line drug for hypertensive patients. Moreover, it challenges the use of atenolol as a reference drug in outcome trials in hypertension. It is noteworthy that the superiority of atenolol over placebo or no treatment in reducing blood pressure did not result in a beneficial effect on mortality or myocardial infarction. The only study showing an advantage for atenolol was the open HEP study, in which one of the outcome variables—ie,
References (38)
- et al.
Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lancet
(2002) - et al.
Beta-blockers in hypertension: the emperor has no clothes—an open letter to present and prospective drafters of new guidelines for the treatment of hypertension
Am J Hypertens
(2003) Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
Lancet
(2003)- et al.
Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension)
Lancet
(1991) - et al.
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
Lancet
(1999) - et al.
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP)
Lancet
(1999) - et al.
Randomised trial of effects of calcium antagonists compared with diuretics and β blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study
Lancet
(2000) - et al.
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal In Hypertension Treatment (INSIGHT)
Lancet
(2000) - et al.
Lowering blood pressure to prevent myocardial infarction and strokes: a new preventive strategy
Health Technol Assess
(2003) - et al.
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
Am J Med
(2003)